

Astellas Announces Changes in Management Structure, Global Function, and Top Management Committees

Tokyo, February 5, 2018 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka) today announced the following changes to its top management structure, global functions and top management committees effective April 1, 2018.

1. Top Management Structure

Top Management	Divisional/Functional Responsibilities
Kenji Yasukawa President & CEO	Drug Discovery Research, Pharmaceutical Technology, Americas Operations, Asia & Oceania Business, EMEA Operations, Japan Sales & Marketing, Internal Auditing, External Relations, MS, QA
Chikashi Takeda CFO	Finance, Information Systems, RWI, Corporate Communications, Procurement
Fumiaki Sakurai CAO & CECO	Ethics & Compliance, Human Resources, Healthcare Policy & CSR, General Affairs, Executive Office
Linda Friedman General Counsel	Intellectual Property, Legal
Bernie Zeiher CMO	Dev, CRQA, MA, PV, RA
Naoki Okamura CSTO	Business Development, Corporate Planning, Product and Portfolio Strategy, Rx+ Business Accelerator

CEO: Chief Executive Officer

CFO: Chief Financial Officer

CAO: Chief Administrative Officer

CECO: Chief Ethics & Compliance Officer

CMO: Chief Medical Officer

CSTO: Chief Strategy Officer

EMEA: Europe, Middle East and Africa

MS: Marketing Strategy

QA: Quality Assurance

RWI: Real World Informatics and Analytics

Dev: Development

CRQA: Clinical and Research Quality Assurance

MA: Medical Affairs

PV: Pharmacovigilance

RA: Regulatory Affairs

2. Global Functions

Enhancement of Finance

To pursue Operational Excellence and realize efficient organizational management to respond rapidly in an evolving and increasingly complex global business environment, a new global function, “Finance” will be established to manage the regional / functional financial functions. The Head of Finance will report directly to the CFO.

Enhancement of Human Resources

To pursue Operational Excellence and realize efficient organizational management to address rapid progress in the globalization and diversification of the human resources functions, a new global function, “Human Resources” will be established to manage the human resources functions in Japan, US and EMEA. The Head of Human Resources will report directly to the CAO.

Enhancement of Internal Auditing

To effectively identify and adequately address critical risks that are global in nature, and provide objective assurance and effective advice through quality execution under a globally unified standard, a new global function, “Internal Auditing” will be established to manage the regional internal auditing functions. The Head of Internal Auditing will report directly to the CEO.

3. Top Management Committees

Abolishment of Japan Management Committee (JMC)

Given the increasing globalization of the Astellas group of organizations, the “Japan Management Committee (JMC),” currently responsible for decision-making on significant corporate governance matters of Astellas Pharma Inc. and its affiliates in Japan, will be abolished due to the decrease in its activities. The responsibilities of the JMC will be integrated into other Management Committees etc., including the “Executive Committee (EC)” for decision-making on significant matters in global management of the Astellas group.

###

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Communications
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473